Ecraprost in lipid emulsion

DRUG2 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Peripheral Vascular Disease

Phase 3

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

CompletedNCT00059657

Tanabe Pharma CorporationPeripheral Vascular Disease

Start: 2001-08-31End: 2005-11-30Target: 280Updated: 2006-05-19

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

TerminatedNCT00059644

Tanabe Pharma CorporationPeripheral Vascular Disease

Start: 2001-07-31End: 2004-06-30Target: 560Updated: 2005-06-24